Buprenorphine was associated with a reduction in the length of treatment among infants with neonatal abstinence syndrome compared to other treatments, a systematic review and meta-analysis found.
Buprenorphine was associated with a reduction in the length of treatment among infants with neonatal abstinence syndrome compared to other treatments, a systematic review and meta-analysis found.